Last updated 2026-06-18
- Went public, Nov 2016
- Acquired NitiLoop, Oct 2022
- Acquired CardioSert for $370k, May 2018
Total raised
$90.5M
Last: 2025-10
Stage
Public
Founded
2010
Headcount
37
HQ
Yokne'am Illit
Sector
Health Tech & Life Sciences
About
Microbot Medical specializes in transformational robotic technologies, focused primarily on the endovascular space. Its LIBERTY Robotic System is the world’s first single-use endovascular robotic system focused on increasing access to robotic technology and revolutionizing the way endovascular procedures are performed.
LIBERTY is the first ever single-use endovascular surgical robotic system designed to streamline endovascular procedures.
In August 2016, U.S.-based StemCells merged with Microbot Medical. In May 2018, the company announced its acquisition of a novel, patent-protected technology from CardioSert. Microbot Medical is now the owner of this technology, including all research and development information, technical know-how, and intellectual property.
Funding history · 14 rounds · $90.5M total
2025-10
$29.2M
2025-08
Grant
$630K
2025-02
$13.0M
2025-01
$7.0M
2024-06
$2.4M
2023-06
$1.5M
2023-06
$2.0M
2023-06
Grant
$440K
2019-12
$10.0M
2019-01
$2.5M
2019-01
$5.9M
2019-01
$3.0M
2017-06
$10.0M
2012-07
Q&A
- What significant regulatory milestone did Microbot Medical achieve in September 2025?
- In September 2025, Microbot Medical Inc. received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, allowing the company to commercialize the system in the U.S. market.
- What was the outcome of Microbot Medical's fundraising program in September 2025?
- In September 2025, Microbot Medical Inc. raised $25.2 million from an options exercise and planned a second offering for an additional $4 million, with the funds intended for the development and commercialization of its LIBERTY Robotic System and potential acquisitions. However, this fundraising program led to a 6.93% decline in its stock price due to potential share dilution.
- Which hospital was the first to adopt Microbot Medical's LIBERTY Endovascular Robotic System?
- In November 2025, Emory University Hospital became the first hospital in the world to adopt Microbot Medical's LIBERTY Endovascular Robotic System.
- What was a key development for Microbot Medical in January 2026?
- In January 2026, Microbot Medical announced key milestones for the year, including continuing its Limited Market Release (LMR) and planning a Full Market Release (FMR) in Q2 2026 for its LIBERTY Endovascular Robotic System, following its FDA 510(k) clearance and adoption by Emory University Hospital in 2025.
- What strategic partnership did Microbot Medical form in December 2023?
- In December 2023, Microbot Medical Inc. announced a collaboration with Corewell Health to enable telerobotics between remote centers using the LIBERTY Endovascular Robotic Surgical System, evaluating the system for remote procedures to improve healthcare accessibility.
- What was the outcome of Microbot Medical's GLP pivotal pre-clinical study in December 2023?
- In December 2023, Microbot Medical Inc. successfully completed its GLP pivotal pre-clinical study for the LIBERTY Endovascular Robotic Surgical System, meeting all study objectives under FDA-required guidelines, which gives the company confidence to proceed to human clinical studies.
- What significant step did Microbot Medical take in December 2024 regarding its LIBERTY system?
- In December 2024, Microbot Medical Inc. submitted a 510(k) premarket notification to the FDA for its LIBERTY Endovascular Robotic System, aiming for commercial launch in the U.S. and anticipating FDA clearance by Q2 2025.
- What was the financial impact of Microbot Medical's cash burn situation as of September 2025?
- As of September 2025, Microbot Medical had $80 million in cash with no debt, providing a cash runway of approximately 7.3 years. However, its annual cash burn of $11 million increased by 23% over the past year, indicating increased investment for future growth despite the company being unprofitable.
Team · 1
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
Machinery & Robotics
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Highlights
1 Patents
Tags
gastroenterologyvascularroboticsminimally-invasiveneurologyendoscopycolonoscopyurologydrug-deliveryimagingmedical-deviceshospitalsdoctorsoptronicsneurovascularmedical-equipmenttelemedicinemedical-technologiescardiovascular
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | microbotmedical.com |
|---|---|
| linkedin.com/company/1502003 | |
| facebook.com/microbotmedical | |
| YouTube | youtube.com/channel/UCXvfiDfCv_R5mDSiyEacsvg |
Identifiers & details
| Founded | 2010-11 |
|---|---|
| Employees (exact) | 37 |
| Offices | Braintree |
| Market cap | $134.3M |
| Status reason | Public on NASDAQ on Nov 2016; |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| NitiLoop | 2022-10 | |
| CardioSert | 2018-05 | $370K |
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2016-11 |